| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
C virus (HCV) infection is a public health problem. Such an infection
is prevalent and aggressive in patients with end-stage kidney disease
(ESKD). The efficacy and the safety of direct-acting antivirus (DAA) in
patients with acute HCV and ESKD are under investigation. The aim of
this study was to assess the safety and efficacy of
sofosbuvir-containing regimens in this difficult-to-treat population.
|Table 1. Patients characteristics, biochemical test, ultrasound results, and treatment course used for treatment|
|Table 2. Virological response to antiviral treatment|
ConclusionsIn conclusion, DAA containing sofosbuvir were suitable for the treatment of acute HCV infection in patient with ESKD without major adverse events.